Tags

Type your tag names separated by a space and hit enter

A modified staging classification for cutaneous T-cell lymphoma.
J Am Acad Dermatol 2001; 45(5):700-6JA

Abstract

BACKGROUND

Despite refinements in the diagnosis of cutaneous T-cell lymphoma (CTCL), since 1979 there have been no changes to the staging of CTCL used to classify mycosis fungoides and Sézary syndrome.

OBJECTIVE

We reviewed the current staging of CTCL and examined the usefulness of a new staging scheme for mycosis fungoides and Sézary syndrome.

METHODS

We determined overall survival of 450 patients with mycosis fungoides and Sézary syndrome using the current and modified staging classifications.

RESULTS

There were no significant differences between survival of patients with stage IB (patches/plaques involving greater than 10% body surface area) and IIA (peripheral adenopathy) disease and of patients with stage IIB (tumor) and III (erythroderma) disease. There was a significant difference in survival between patients with extensive patch versus extensive plaque stage disease. Modification of the current classification by splitting T2 into patch versus plaque stage disease and incorporating tumors and erythroderma into stage III proved superior to the current scheme in predicting overall survival.

CONCLUSION

Modification of the current staging classification for CTCL yields subgroups useful in the prognostic assessment of CTCL.

Authors+Show Affiliations

Cutaneous Oncology Division, University of California San Francisco Cancer Center, 4th Floor, 1600 Devisadero Street, San Francisco, CA 94115, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11606919

Citation

Kashani-Sabet, M, et al. "A Modified Staging Classification for Cutaneous T-cell Lymphoma." Journal of the American Academy of Dermatology, vol. 45, no. 5, 2001, pp. 700-6.
Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001;45(5):700-6.
Kashani-Sabet, M., McMillan, A., & Zackheim, H. S. (2001). A modified staging classification for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 45(5), pp. 700-6.
Kashani-Sabet M, McMillan A, Zackheim HS. A Modified Staging Classification for Cutaneous T-cell Lymphoma. J Am Acad Dermatol. 2001;45(5):700-6. PubMed PMID: 11606919.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A modified staging classification for cutaneous T-cell lymphoma. AU - Kashani-Sabet,M, AU - McMillan,A, AU - Zackheim,H S, PY - 2001/10/19/pubmed PY - 2002/1/5/medline PY - 2001/10/19/entrez SP - 700 EP - 6 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 45 IS - 5 N2 - BACKGROUND: Despite refinements in the diagnosis of cutaneous T-cell lymphoma (CTCL), since 1979 there have been no changes to the staging of CTCL used to classify mycosis fungoides and Sézary syndrome. OBJECTIVE: We reviewed the current staging of CTCL and examined the usefulness of a new staging scheme for mycosis fungoides and Sézary syndrome. METHODS: We determined overall survival of 450 patients with mycosis fungoides and Sézary syndrome using the current and modified staging classifications. RESULTS: There were no significant differences between survival of patients with stage IB (patches/plaques involving greater than 10% body surface area) and IIA (peripheral adenopathy) disease and of patients with stage IIB (tumor) and III (erythroderma) disease. There was a significant difference in survival between patients with extensive patch versus extensive plaque stage disease. Modification of the current classification by splitting T2 into patch versus plaque stage disease and incorporating tumors and erythroderma into stage III proved superior to the current scheme in predicting overall survival. CONCLUSION: Modification of the current staging classification for CTCL yields subgroups useful in the prognostic assessment of CTCL. SN - 0190-9622 UR - https://www.unboundmedicine.com/medline/citation/11606919/A_modified_staging_classification_for_cutaneous_T_cell_lymphoma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(01)13000-8 DB - PRIME DP - Unbound Medicine ER -